干细胞移植后艾滋病毒-1缓解，但无CCR5Δ32突变

IF 58.7 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Nature Medicine Pub Date : 2024-11-06 DOI:10.1038/s41591-024-03365-0

{"title":"干细胞移植后艾滋病毒-1缓解，但无CCR5Δ32突变","authors":"","doi":"10.1038/s41591-024-03365-0","DOIUrl":null,"url":null,"abstract":"We report the first case of a person achieving sustained HIV-1 remission after transplantation with allogeneic hematopoietic stem cells that express wild-type CCR5 and thus are permissive to HIV-1 infection. The 53-year-old man received the transplant in 2018 to treat a rare myeloid sarcoma and has not experienced viral rebound since discontinuing antiretroviral therapy in November 2021.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":null,"pages":null},"PeriodicalIF":58.7000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"HIV-1 remission following stem cell transplant without CCR5Δ32 mutation\",\"authors\":\"\",\"doi\":\"10.1038/s41591-024-03365-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We report the first case of a person achieving sustained HIV-1 remission after transplantation with allogeneic hematopoietic stem cells that express wild-type CCR5 and thus are permissive to HIV-1 infection. The 53-year-old man received the transplant in 2018 to treat a rare myeloid sarcoma and has not experienced viral rebound since discontinuing antiretroviral therapy in November 2021.\",\"PeriodicalId\":19037,\"journal\":{\"name\":\"Nature Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":58.7000,\"publicationDate\":\"2024-11-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41591-024-03365-0\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41591-024-03365-0","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

我们报告了首例移植了表达野生型CCR5从而允许HIV-1感染的异体造血干细胞后实现HIV-1持续缓解的病例。这名 53 岁的男子于 2018 年接受了移植，以治疗罕见的骨髓肉瘤，自 2021 年 11 月停止抗逆转录病毒疗法以来，他的病毒没有反弹。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

HIV-1 remission following stem cell transplant without CCR5Δ32 mutation

We report the first case of a person achieving sustained HIV-1 remission after transplantation with allogeneic hematopoietic stem cells that express wild-type CCR5 and thus are permissive to HIV-1 infection. The 53-year-old man received the transplant in 2018 to treat a rare myeloid sarcoma and has not experienced viral rebound since discontinuing antiretroviral therapy in November 2021.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Medicine 医学-生化与分子生物学

CiteScore

100.90

自引率

0.70%

发文量

525

审稿时长

1 months

期刊介绍： Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors. Nature Medicine consider all types of clinical research, including: -Case-reports and small case series -Clinical trials, whether phase 1, 2, 3 or 4 -Observational studies -Meta-analyses -Biomarker studies -Public and global health studies Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.